FDA, EU agree to review Biogen's MS drug Plegridy

07/22/2013 | Pharmaceutical Business Review Online · PMLive.com (U.K.)

The FDA and the European Medicines Agency have accepted Biogen Idec's marketing applications for Plegridy, or peginterferon beta-1a, a subcutaneous injectable formulation for the treatment of relapsing forms of multiple sclerosis. The applications included data from the late-stage ADVANCE trial.

View Full Article in:

Pharmaceutical Business Review Online · PMLive.com (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA